GENETIC RISK FACTORS OF ANTHRACYCLINE CARDIOTOXICITY - RELEVANT POLYMORPHISMS IDENTIFIED IN ENZYMES AND TRANSPORTERS OF ANTHRACYCLINE PHARMACOKINETICS

被引：0
|
作者：
Kutszegi, Nora Zsofia [1 ]
Semsei, Agnes F. [1 ]
Lautner-Csorba, Orsolya [1 ]
Hegyi, Marta [2 ]
Szabolcs, Judit [2 ]
Benyo, Gabor [3 ]
Szalai, Csaba [1 ,4 ]
Kovacs, Gabor T. [2 ]
Erdelyi, Daniel Janos [2 ]
机构：
[1] Semmelweis Univ, Dept Genet Cell & Immunobiol, H-1085 Budapest, Hungary
[2] Semmelweis Univ, Dept Paediat 2, H-1085 Budapest, Hungary
[3] Szent Laszlo Hosp, Budapest, Hungary
[4] Csertex Res Lab, Budapest, Hungary
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1101 / 1101
页数：1
相关论文
共 50 条
  • [31] Undiagnosed hypertension trumps trastuzumab as a risk factor for anthracycline cardiotoxicity
    Kotwinski, P.
    Smith, G.
    Sanders, J.
    Cooper, J.
    Teis, A.
    Jones, A.
    Pennell, D.
    Montgomery, H.
    Ma, L.
    EUROPEAN HEART JOURNAL, 2012, 33 : 299 - 299
  • [32] Single Nucleotide Polymorphisms and Anthracycline Cardiotoxicity in Children: Potential Implications for Adult Oncology
    Atkins, Carl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) : 3563 - 3563
  • [33] Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence
    Ni, Ming-Ming
    Yang, Ju-Fei
    Miao, Jing
    Xu, Jin
    CLINICAL GENETICS, 2024, 105 (02) : 115 - 129
  • [34] Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis
    Zhang, Meilin
    Yang, Hongguang
    Xu, Changcun
    Jin, Feng
    Zheng, Ang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity
    Ding, Yonghe
    Du, Ke
    Niu, Yu-Juan
    Wang, Yong
    Xu, Xiaolei
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [36] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity
    Aminkeng, Folefac
    Ross, Colin J. D.
    Rassekh, Shahrad R.
    Hwang, Soomi
    Rieder, Michael J.
    Bhavsar, Amit P.
    Smith, Anne
    Sanatani, Shubhayan
    Gelmon, Karen A.
    Bernstein, Daniel
    Hayden, Michael R.
    Amstutz, Ursula
    Carleton, Bruce C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) : 683 - 695
  • [37] Discovery of Critical Transcription Factors as Biomarkers in Anthracycline-Induced Cardiotoxicity
    Faber, J.
    Asensio, J. Ochoteco
    Nguyen, N.
    Caiment, F.
    van den Beucken, T.
    TOXICOLOGY LETTERS, 2023, 384 : S79 - S80
  • [38] Influence of genetic polymorphisms in drug metabolism enzymes and transporters on pharmacokinetics of different fluvastatin formulations
    Qian XIANG
    Jun-yu XU
    Ling-yue MA
    Nan ZHAO
    Xiao-dan ZHANG
    Qiu-fen XIE
    Zhuo ZHANG
    Xia ZHAO
    Yi-min CUI
    中国药理学与毒理学杂志, 2018, 32 (04) : 317 - 317
  • [39] The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations
    Qian Xiang
    Weidang Wu
    Nan Zhao
    Chuan Li
    Junyu Xu
    Lingyue Ma
    Xiaodan Zhang
    Qiufen Xie
    Zhuo Zhang
    Jiancheng Wang
    Weiren Xu
    Xia Zhao
    Yimin Cui
    AsianJournalofPharmaceuticalSciences, 2020, 15 (02) : 264 - 272
  • [40] The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations
    Xiang, Qian
    Wu, Weidang
    Zhao, Nan
    Li, Chuan
    Xu, Junyu
    Ma, Lingyue
    Zhang, Xiaodan
    Xie, Qiufen
    Zhang, Zhuo
    Wang, Jiancheng
    Xu, Weiren
    Zhao, Xia
    Cui, Yimin
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 15 (02) : 264 - 272
12345